M&A / Deals Roche places a $1bn bet on C4T degrader-antibody conjugates PharmaphorumRoche is paying $20 million upfront to secure rights to two degrader-antibody conjugates (DACs) for cancer developed by longtime partner C4T.M&A / DealsOncologyRead full story pharminent April 10, 2026 (Last updated: April 10, 2026) Pharmaphorum Roche is paying $20 million upfront to secure rights to two degrader-antibody conjugates (DACs) for cancer developed by longtime partner C4T. M&A / DealsOncologyRead full story Post navigation Previous: Roche and C4 Therapeutics to advance degrader-antibody conjugates researchNext: GSK again pulls application for leucovorin, touted by FDA as potential autism treatment Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
